These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 16258475

  • 1. Are targeted therapies really targeted?
    Schilsky RL.
    Clin Adv Hematol Oncol; 2003 Dec; 1(12):722-3. PubMed ID: 16258475
    [No Abstract] [Full Text] [Related]

  • 2. Developing targeted therapies for lung cancer.
    Gandara DR.
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):648-9, 690. PubMed ID: 16258461
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Targeted therapies: aiming for the bull's-eye.
    Gaguski ME.
    ONS Connect; 2007 Jul; 22(7):8-12. PubMed ID: 17694778
    [No Abstract] [Full Text] [Related]

  • 5. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
    Perry WL, Weitzman A.
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.
    Arteaga CL, Baselga J.
    Clin Cancer Res; 2003 May; 9(5):1579-89. PubMed ID: 12738709
    [No Abstract] [Full Text] [Related]

  • 8. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV.
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [Abstract] [Full Text] [Related]

  • 9. A dose of reality for rational therapies.
    Nat Biotechnol; 2005 Mar; 23(3):267. PubMed ID: 15765066
    [No Abstract] [Full Text] [Related]

  • 10. [The pathologist and targeted therapies in oncology].
    Bertheau P.
    Ann Pathol; 2009 Nov; 29 Spec No 1():S69-70. PubMed ID: 19887258
    [No Abstract] [Full Text] [Related]

  • 11. Targeted therapies: a nursing perspective.
    Kay P.
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):1-4. PubMed ID: 16616280
    [Abstract] [Full Text] [Related]

  • 12. Newer phase II trial designs gaining ground.
    Benowitz S.
    J Natl Cancer Inst; 2007 Oct 03; 99(19):1428-9. PubMed ID: 17895467
    [No Abstract] [Full Text] [Related]

  • 13. Novel therapeutic targets.
    Farley J, Birrer MJ.
    Cancer Treat Res; 2009 Oct 03; 149():63-84. PubMed ID: 19763431
    [No Abstract] [Full Text] [Related]

  • 14. Antibody-targeted drugs for the therapy of cancer.
    Pietersz GA, Krauer K.
    J Drug Target; 1994 Oct 03; 2(3):183-215. PubMed ID: 7812691
    [Abstract] [Full Text] [Related]

  • 15. Clinical cancer research 2001: new agents and therapies.
    Verweij J, de Vries EG.
    Drug Resist Updat; 2001 Aug 03; 4(4):217-23. PubMed ID: 11991676
    [No Abstract] [Full Text] [Related]

  • 16. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O, Bozec A, Fischel JL, Milano G.
    Crit Rev Oncol Hematol; 2007 Apr 03; 62(1):53-61. PubMed ID: 17324578
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Modern molecular approaches to drug design and discovery.
    Ojima I.
    Acc Chem Res; 2008 Jan 03; 41(1):2-3. PubMed ID: 18193819
    [No Abstract] [Full Text] [Related]

  • 20. Targeted therapy in lung cancers: hopes and challenges.
    Chen H, Wang X.
    Expert Rev Clin Pharmacol; 2011 Nov 03; 4(6):659-61. PubMed ID: 22111850
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.